Eraquell 18.7 mg/g Oral Paste

Nchi: Uingereza

Lugha: Kiingereza

Chanzo: VMD (Veterinary Medicines Directorate)

Viambatanisho vya kazi:

Ivermectin

Inapatikana kutoka:

Virbac

ATC kanuni:

QP54AA01

INN (Jina la Kimataifa):

Ivermectin

Dawa fomu:

Oral paste

Dawa ya aina:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Kundi la matibabu:

Horses

Eneo la matibabu:

Endectocide

Idhini hali ya:

Authorized

Idhini ya tarehe:

2000-11-16

Tabia za bidhaa

Revised: December 2015
AN: 01163/2015
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
ERAQUELL 18.7 mg/g Oral Paste
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Ivermectin
............................................................
18.7
mg/g.
EXCIPIENTS:
Titanium dioxide (E171) ......................................
0.02 g/g.
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Oral paste.
White and thick paste.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Roundworms in the stomach and intestines.
Large strongyles:
_Strongylus vulgaris: _adults and 4
th
larval (arterial) stages
_Strongylus edentatus: _adults and 4
th
larval (tissue) stages
_Strongylus equinus: _adults
Small strongyles, adults:
_Cyathostomum_ spp.
_Cylicocyclus_ spp.
_Cylicodontophorus_ spp.
_Cylicostephanus_ spp.
_Gyalocephalus _spp.
Hairworms:
_Trichostrongylus axei: _adults
Pinworms:
_Oxyuris equi: _adults and immatures
Ascarids:
_Parascaris equorum: _adults
Revised: December 2015
AN: 01163/2015
Page 2 of 6
Intestinal threadworms:
_Strongyloides westeri: _adults
Large-mouth stomach worms:
_Habronema muscae: _adults
Neck threadworms:
_Onchocerca_ spp. (microfilariae)
Lungworms:
_Dictyocaulus arnfieldi: _adult and immature
Stomach bots:
_Gasterophilus_ spp.: oral and gastric larval stages
4.3
CONTRA-INDICATIONS
Do not use in dogs or cats as severe adverse reactions may occur.
Do not use in cases of known hypersensitivity to the active substance.
See also section 4.11 “Withdrawal periods”.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Strategies that should be avoided because they might lead to an
increased risk of
development of resistance to anthelmintic drugs include:
•
Too frequent and repeated use of anthelmintics from the same class
over an
extended period of time.
•
Underdosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of calibration of the dosi